Sky Labs presented clinical validation of CART, a ring-based blood pressure monitor using photoplethysmography and AI, demonstrating 80% data capture in 24-hour monitoring of atrial fibrillation patients and high agreement with standard ambulatory blood pressure devices in severe heart failure cases. Continuous, non-invasive blood pressure monitoring at scale addresses a critical gap in detecting arrhythmias and hemodynamic instability outside clinical settings.
Key Points
- Ring-type monitor captures nocturnal blood pressure dipping patterns with 80% data success rate
- Validation in severe heart failure shows agreement with gold-standard 24-hour ambulatory monitoring
- Device now prescribed across 2,000+ Korean institutions with regulatory reimbursement approval
Longevity Analysis
Continuous cardiovascular monitoring shifts detection from episodic clinical snapshots to longitudinal signal capture, enabling earlier identification of hemodynamic decompensation, arrhythmia burden, and nocturnal pressure abnormalities that correlate with adverse events and progression. The 80% capture rate in atrial fibrillation patients demonstrates sufficient signal fidelity to decode meaningful circulatory patterns—particularly the nocturnal dipping response, a known prognostic marker. This technology supports the foundational step of accurate biometric feedback, which is prerequisite to any effective intervention or monitoring protocol; wearable validation at scale also addresses adherence barriers inherent to clinic-based or home-based manual monitoring.
Original published by LT Wire.